Agents that target these abnormalities, including IDH inhibitors (e.g., ivosidenib and enasidenib), FLT3 inhibitors (e.g., midostaurin, gilteritinib, quizartinib, and sorafenib), and others, have offered an opportunity for remission with AML harboring targetable mutations[17,18]. This evidence concerns the gene FLT3 and acute myeloid leukemia.